

1 **ABSTRACT OF THE DISCLOSURE**

2 The present invention relates to a method for treating immune
3 disorders and a method for lowering the levels of T-cell activation and
4 proliferation in a human comprising administering CD30 or a biologically
5 functional equivalent thereof to a human afflicted with immune disorders. The
6 present invention also relates to a pharmaceutical composition for treating
7 immune disorders in a human comprising a therapeutically effective amount of
8 CD30 or a biologically functional equivalent thereof, and a pharmaceutically
9 acceptable carrier, excipient or diluent.